Investing.com - Tempest Therapeutics reported on Tuesday third quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
Tempest Therapeutics announced earnings per share of $-0.6600 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.7600 on revenue of $0.00.
Tempest Therapeutics shares are down 41.36% from the beginning of the year and are trading at $1.6200 , down-from-52-week-high.
Tempest Therapeutics shares lost 10.99% in intra-day trade after the report.
Tempest Therapeutics follows other major Healthcare sector earnings this month
Tempest Therapeutics's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar